$150M Offering Priced at Premium to Market, Extending Cash Runway After FDA Approval
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune priced a $150 million underwritten offering just three days after securing FDA accelerated approval for TUDRIQEV in advanced melanoma. The deal includes 9.7 million shares at $12.06 and 2.7 million pre-funded warrants at $12.0599, a premium to the $12.63 market price — signaling strong institutional demand. This follows the going concern warning in the June 10-K, where cash was only sufficient into Q1 2027. The raise materially extends the runway to support the commercial launch and ongoing pipeline development. Closing is expected August 11.
At the time of this announcement, REPL was trading at $12.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.50 to $13.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.